Death is ubiquitous and inevitable. Many of us have had some experience with death in our personal lives, and as clinicians and researchers, we address death either directly or indirectly, almost every day. Still, there remains significant debate and gaps in knowledge regarding the biology of death, as well as the medical and ethical issues concerning death and dying. This multi-disciplinary issue of the *Yale Journal of Biology and Medicine* is devoted to exploring the major advances and unresolved questions about death. We present 25 articles representing contributions from researchers that examine death at different biological scales and that provide legal, medical, and ethical perspectives on the process of dying.

Death has traditionally been determined based on cardiopulmonary standards where "physicians would feel for the pulse, listen for breathing, hold a mirror before the nose to test for condensation, and look to see if the pupils were fixed \[[@R1]\]." Advances in life-sustaining treatment rendered these criteria insufficient, as heart and lung functions could now be performed artificially. The consequent redefinition of death to include neurologic criteria is reviewed by Junn and Hwang, who additionally highlight significant variability in the determination of brain death. While advances in life-sustaining treatment enabled some patients the opportunity to recover from critical illnesses, this was not the case for many others, and over time, both clinicians and the public struggled to care for patients with minimal prospects of recovery. This led to an increased discussion about end of life care, including living wills and physician aid in dying. A study by Hetzler and colleagues show divergent physician views on physician-assisted suicide (PAS). While 60 percent of physicians in the United States support the legalization of PAS, only 13 percent of those who supported its legalization would be willing to participate. They further show that physician views are informed by a myriad of factors, including spiritual/religious beliefs and lack of training/expertise; physicians additionally expressed ethical and safety concerns about the potential legalization of euthanasia following PAS legalization and sufficient access to palliative care.

Also included in this issue are two articles that explore the experiences of physicians who are tasked with providing end of life care. The first, by Moore *et al*. discusses what constitutes a "good death" for an infant and their family. In the second, McKillip and colleagues detail their approach to prognostication given dramatic and unexpected perimortem changes in patient condition and autonomy. McKillip *et al*. state that "all clinicians strive to uphold their duty to be worthy of the trust of their patients." However, as further discussed in our issue, determining how to fulfill this duty can become complicated when treating patients nearing the end of their lives.

In addition to ethical and medical issues surrounding death and dying, this issue also includes insights on some of the leading causes of morbidity and mortality. Sepsis is a major cause of death in hospitals and is the result of an uncontrolled immune response to infection \[[@R2]\]. As reviewed by Caraballo and Jaimes, sepsis presents with heterogeneous pathophysiology across patients, but ultimately leads to widespread organ failure and death in around 20 percent of patients \[[@R2]\]. High patient-to-patient variability in the progression of sepsis is a key challenge in clinical assessment. Thus, the authors review novel techniques for diagnosis and mortality risk measurement, and advocate for improved public health strategies to reduce the global burden of sepsis. Also featured is an interview with Dr. Vincent DeVita conducted by Yale School of Public Health masters student Huaqi Li about advances in the treatment of cancer, the second leading cause of death worldwide \[[@R3]\]. Dr. DeVita is an oncologist and the former Director of the Yale Cancer Center, the National Cancer Institute and former Physician-in-Chief at Memorial Sloan Kettering Cancer Center. In the interview, he discusses his pioneering work in combination chemotherapy and offers his unique insight into the past and future of cancer treatment.

The term "apoptosis" was first used in 1972 to describe programmed cell death (PCD), which Kerr *et al*. astutely recognized as "a basic biological phenomenon with wide-ranging implications \[[@R4]\]." As reviewed by Galimberti *et al*., we now know that PCD occurs extensively during disease and development, and that there are many different cell death modalities. Moreover, the death of a cell itself can serve as an input for downstream pathways, including those that regulate pathogen response and inflammation. In their review, Lee and Overholtzer detail the ways whereby cells may continue to affect tissue physiology even after death. One pathway through which this can occur is entosis, which was discovered by Michael Overholtzer in 2007 \[[@R5]\]. Entosis describes the process in which a live cell is internalized by another cell and subsequently dies, resulting in nutrient release. Lee and Overholtzer note that the induction of entosis has been observed in cancer cells under starvation stress and speculate that entosis could enable the survival of cancer cell populations in the harsh tumor microenvironment.

Dysregulation in cell death commonly underlies pathologies, and an understanding of these mechanisms may inform the development of future therapies. In their review, Tompkins and Thorburn explain that despite continued proliferation, cancer cells are generally closer to their apoptotic threshold compared to normal cells. Since cancer cells rely on autophagy for obtaining the necessary nutrients for growth and survival, they propose the inhibition of autophagy as a means of providing a "pro-apoptotic push" to promote cancer cell death. On a similar note, Wang discusses DNA damage induced cell death and explores the exploitation of common defects in the DNA damage response in cancer cells in current and future anticancer therapies.

PCD may even have implications beyond individual organisms. Durand *et al*. explain that although PCD was first described in eukaryotes, recent research shows that PCD also occurs in single-celled organisms and was likely essential in the emergence of multicellularity. In communities of single-celled organisms, PCD may have served as a means of cell-to-cell communication and coordination. This likely enabled cooperative behaviors like the division of labor, resulting in mutually dependent groups of cells that precede the evolution of multicellularity. PCD plays a role in the maintenance of social structure in eusocial insect colonies. It has been shown that induced PCD leads to the sterilization of certain colony members, resulting in reproductive division of labor.

Our understanding of death is far from complete. In this issue, we aimed to highlight recent advances in our understanding of death at different biological scales, as well as from the perspective of multiple disciplines as it relates to end of life care. The legal, ethical, and medical viewpoints presented in this issue examine our relationship with death and clinician responsibility in care at the end of life, and carry implications on policy, medical practice, and education. In addition, we shed light on some of the spectacular advances in elucidating the biology of death as well as promising future work on molecular mechanisms and therapeutic applications. We hope that the articles presented here will help guide and enlighten future research on death in all forms and efforts to improve health outcomes.
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